These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18595508)

  • 1. [New tumour markers useful in diagnostics and monitoring of cervical cancer].
    Bedkowska GE; Lawicki S; Szmitkowski M
    Przegl Lek; 2007; 64(12):1022-7. PubMed ID: 18595508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
    Gadducci A; Tana R; Cosio S; Genazzani AR
    Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.
    Gaarenstroom KN; Bonfrer JM; Korse CM; Kenter GG; Kenemans P
    Anticancer Res; 1997; 17(4B):2955-8. PubMed ID: 9329574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
    Hung YC; Shiau YC; Chang WC; Kao CH; Lin CC
    Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tumor markers useful for diagnosis and monitoring of lung neoplasm].
    Ławicki S; Mroczko B; Szmitkowski M
    Postepy Hig Med Dosw; 2002; 56(1):93-118. PubMed ID: 11993454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor markers in uterine cancers].
    Fukasawa I; Kousaka N; Kun Z; Inaba N
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):333-40. PubMed ID: 11865645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular markers of carcinogenesis in the diagnostics of cervical cancer].
    Bedkowska GE; Ławicki S; Szmitkowski M
    Postepy Hig Med Dosw (Online); 2009 Feb; 63():99-105. PubMed ID: 19252468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
    Gadducci A; Tana R; Fanucchi A; Genazzani AR
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S23-6. PubMed ID: 17727924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnostic significance of tumor markers for gynecologic malignancies].
    Aoki D; Hirasawa A; Susumu N
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):411-6. PubMed ID: 15791829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The value of marker antigens TPS, SCC and CEA in diagnosis, evaluation of histologic type and clinical disease progression in patients with cervical carcinoma].
    Zakrzewska I
    Pol Merkur Lekarski; 2001 Jan; 10(55):21-3. PubMed ID: 11320545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The plasma levels and diagnostic utility of stem cell factor (SCF) and macrophage-colony stimulating factor (M-CSF) in cervical cancer patients].
    Lawicki S; Bedkowska E; Gacuta-Szumarska E; Knapp P; Szmitkowski M
    Pol Merkur Lekarski; 2008 Jul; 25(145):38-42. PubMed ID: 18839612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers.
    Sidorkiewicz I; Zbucka-Krętowska M; Zaręba K; Lubowicka E; Zajkowska M; Szmitkowski M; Gacuta E; Ławicki S
    BMC Cancer; 2019 Apr; 19(1):398. PubMed ID: 31035945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neoplasm markers useful for diagnosis and monitoring of colonic neoplasms].
    Ławicki S; Mroczko B; Szmitkowski M
    Postepy Hig Med Dosw; 2002; 56(5):617-34. PubMed ID: 12596691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia.
    Tramonti G; Ferdeghini M; Donadio C; Norpoth M; Annichiarico C; Bianchi R; Bianchi C
    Cancer Detect Prev; 2000; 24(1):86-90. PubMed ID: 10757127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tumor makrers in cervical cancer].
    Markowska J
    Ginekol Pol; 2007 Sep; 78(9):715-8. PubMed ID: 18159826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor markers in epithelial ovarian cancer].
    Di Cocco B; Calabretta F; Alghisi F; Salesi N; Bossone G
    Minerva Ginecol; 2003 Aug; 55(4):327-32. PubMed ID: 14581857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.
    Molina R; Filella X; Augé JM; Bosch E; Torne A; Pahisa J; Lejarcegui JA; Rovirosa A; Mellado B; Ordi J; Biete A
    Anticancer Res; 2005; 25(3A):1765-71. PubMed ID: 16033097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The plasma levels and diagnostic utility of stem cell factor and macrophage--colony stimulating factor in endometrial cancer patients].
    Lawicki S; Bedkowska E; Gacuta-Szumarska E; Czygier M; Szmitkowski M
    Przegl Lek; 2007; 64(12):987-90. PubMed ID: 18595499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness.
    Forni F; Ferrandina G; Deodato F; Macchia G; Morganti AG; Smaniotto D; Luzi S; D'Agostino G; Valentini V; Cellini N; Giardina B; Scambia G
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1145-9. PubMed ID: 17689030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.